Cargando…
Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial
INTRODUCTION: The incidence of erectile dysfunction (ED) increases with age in mainland China and phosphodiesterase 5 inhibitors (PDE5i) are the major drugs used for its treatment. AIM: To determine the efficacy and safety of Chinese developed avanafil as therapy for ED in China. METHODS: This phase...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240155/ https://www.ncbi.nlm.nih.gov/pubmed/33685839 http://dx.doi.org/10.1016/j.esxm.2021.100337 |
_version_ | 1783715157251194880 |
---|---|
author | Jiang, Hui Lin, Haocheng Li, Fubiao Dai, Yutian Zhang, Xiangsheng Jiang, Tao Deng, Junhong |
author_facet | Jiang, Hui Lin, Haocheng Li, Fubiao Dai, Yutian Zhang, Xiangsheng Jiang, Tao Deng, Junhong |
author_sort | Jiang, Hui |
collection | PubMed |
description | INTRODUCTION: The incidence of erectile dysfunction (ED) increases with age in mainland China and phosphodiesterase 5 inhibitors (PDE5i) are the major drugs used for its treatment. AIM: To determine the efficacy and safety of Chinese developed avanafil as therapy for ED in China. METHODS: This phase III trial was carried out in 7 medical centers in China. Eligible subjects suffering from ED were allocated randomly into 3 groups (ratio 1:1:1) and orally received a placebo, 100 or 200 mg avanafil for a total of 12 weeks. MAIN OUTCOME MEASURES: The primary endpoint was changes in erectile function (EF) domain scores according to the International Index of EF (IIEF) questionnaire from baseline to week 12 of therapy. Secondary endpoints assessments were changes in the response rates of SEP, Q2 and Q3; changes in IIEF other domain scores. Safety evaluation monitored treatment-emergent adverse events (TEAEs), serious TEAEs, laboratory test results, vital signs and electrocardiographs. RESULTS: Of 218 randomized ED subjects, 182 (83.5%) completed the study. After 12-week therapy, alterations from baseline of the mean IIEF-EF domain scores in the 100 mg and 200 mg groups were greater than for the placebo (all P < .05) group. The changes in mean SEP Q2 response rates from baseline to week 12 in the placebo, 100 mg and 200 mg groups were 5.4%, 22.3% and 22.1%, and SEP Q3 response rate were 22.7%, 42.6% and 38.1%, respectively. Avanafil treatment (regardless of dose) improved EF vs placebo for most of other secondary efficacy endpoints studied (all P < .05). No differences were detected in efficacy endpoints between the 100 and 200 mg dosage groups (all P > .05) or in the incidence of TEAEs and drug-related TEAEs among the 3 groups (all P > .05). CONCLUSION: Avanafil (100 or 200 mg) was effective and generally well tolerated in Chinese subjects with ED. Jiang H, Lin H, Li F, et al. Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial. Sex Med 2021;9:100337. |
format | Online Article Text |
id | pubmed-8240155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-82401552021-06-29 Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial Jiang, Hui Lin, Haocheng Li, Fubiao Dai, Yutian Zhang, Xiangsheng Jiang, Tao Deng, Junhong Sex Med Original Research INTRODUCTION: The incidence of erectile dysfunction (ED) increases with age in mainland China and phosphodiesterase 5 inhibitors (PDE5i) are the major drugs used for its treatment. AIM: To determine the efficacy and safety of Chinese developed avanafil as therapy for ED in China. METHODS: This phase III trial was carried out in 7 medical centers in China. Eligible subjects suffering from ED were allocated randomly into 3 groups (ratio 1:1:1) and orally received a placebo, 100 or 200 mg avanafil for a total of 12 weeks. MAIN OUTCOME MEASURES: The primary endpoint was changes in erectile function (EF) domain scores according to the International Index of EF (IIEF) questionnaire from baseline to week 12 of therapy. Secondary endpoints assessments were changes in the response rates of SEP, Q2 and Q3; changes in IIEF other domain scores. Safety evaluation monitored treatment-emergent adverse events (TEAEs), serious TEAEs, laboratory test results, vital signs and electrocardiographs. RESULTS: Of 218 randomized ED subjects, 182 (83.5%) completed the study. After 12-week therapy, alterations from baseline of the mean IIEF-EF domain scores in the 100 mg and 200 mg groups were greater than for the placebo (all P < .05) group. The changes in mean SEP Q2 response rates from baseline to week 12 in the placebo, 100 mg and 200 mg groups were 5.4%, 22.3% and 22.1%, and SEP Q3 response rate were 22.7%, 42.6% and 38.1%, respectively. Avanafil treatment (regardless of dose) improved EF vs placebo for most of other secondary efficacy endpoints studied (all P < .05). No differences were detected in efficacy endpoints between the 100 and 200 mg dosage groups (all P > .05) or in the incidence of TEAEs and drug-related TEAEs among the 3 groups (all P > .05). CONCLUSION: Avanafil (100 or 200 mg) was effective and generally well tolerated in Chinese subjects with ED. Jiang H, Lin H, Li F, et al. Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial. Sex Med 2021;9:100337. Elsevier 2021-03-06 /pmc/articles/PMC8240155/ /pubmed/33685839 http://dx.doi.org/10.1016/j.esxm.2021.100337 Text en Copyright © 2021, International Society of Sexual Medicine. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Jiang, Hui Lin, Haocheng Li, Fubiao Dai, Yutian Zhang, Xiangsheng Jiang, Tao Deng, Junhong Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial |
title | Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial |
title_full | Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial |
title_fullStr | Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial |
title_full_unstemmed | Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial |
title_short | Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial |
title_sort | efficacy and safety of avanafil in chinese subjects with erectile dysfunction: a multi-center, randomized, double-blinded, placebo-controlled phase iii clinical trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240155/ https://www.ncbi.nlm.nih.gov/pubmed/33685839 http://dx.doi.org/10.1016/j.esxm.2021.100337 |
work_keys_str_mv | AT jianghui efficacyandsafetyofavanafilinchinesesubjectswitherectiledysfunctionamulticenterrandomizeddoubleblindedplacebocontrolledphaseiiiclinicaltrial AT linhaocheng efficacyandsafetyofavanafilinchinesesubjectswitherectiledysfunctionamulticenterrandomizeddoubleblindedplacebocontrolledphaseiiiclinicaltrial AT lifubiao efficacyandsafetyofavanafilinchinesesubjectswitherectiledysfunctionamulticenterrandomizeddoubleblindedplacebocontrolledphaseiiiclinicaltrial AT daiyutian efficacyandsafetyofavanafilinchinesesubjectswitherectiledysfunctionamulticenterrandomizeddoubleblindedplacebocontrolledphaseiiiclinicaltrial AT zhangxiangsheng efficacyandsafetyofavanafilinchinesesubjectswitherectiledysfunctionamulticenterrandomizeddoubleblindedplacebocontrolledphaseiiiclinicaltrial AT jiangtao efficacyandsafetyofavanafilinchinesesubjectswitherectiledysfunctionamulticenterrandomizeddoubleblindedplacebocontrolledphaseiiiclinicaltrial AT dengjunhong efficacyandsafetyofavanafilinchinesesubjectswitherectiledysfunctionamulticenterrandomizeddoubleblindedplacebocontrolledphaseiiiclinicaltrial |